Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Bad Dürrnberg – page 11

328 clinical trials in Bad Dürrnberg, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Bad Dürrnberg at a glance
328
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

328 trials in Bad Dürrnberg

Open in trial search

Partial seizures

Not yet recruiting

Study on the Effectiveness and Safety of BHV-7000 for Adults with Refractory Focal Onset Epilepsy

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:BHV-7000
  • Sponsor:Biohaven Therapeutics Ltd.

Narcolepsy

Not yet recruiting

Study on TAK-861 for Treating Narcolepsy with Cataplexy in Patients

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Oveporexton
  • Sponsor:Takeda Development Center Americas Inc.

Epidermolysis bullosa

Not yet recruiting

Study on ABCB5+ MSCs for Recessive Dystrophic and Junctional Epidermolysis Bullosa Patients

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:ALLO-APZ2-EB
  • Sponsor:Rheacell GmbH & Co. KG

Efficacy of efgartigimod alfa as first‑line add‑on to IV methylprednisolone for moderate‑to‑severe attacks in patients with demyelinating diseases

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Medizinische Hochschule Hannover

Narcolepsy

Not yet recruiting

A Randomized, Double‑Blind Study of ORX750 versus Placebo for Excessive Daytime Sleepiness in Adults with Narcolepsy (Type 1 and Type 2)

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:ORX750
  • Sponsor:Centessa Pharmaceuticals UK Limited

Efficacy of neoadjuvant sacituzumab govitecan versus standard drug combination in patients with endocrine non‑responsive ER+/HER2‑negative early breast cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Verein Zur Praevention Und Therapie Boesartiger Erkrankungen Austrian Breast And Colorectal Cancer Study Group

Adenocarcinoma pancreas+1

Not yet recruiting

Diagnostic Performance of [68Ga]Ga-HKG301 PET/CT with FAP-2286 in Patients with Pancreatic Adenocarcinoma and Invasive Lobular Breast Cancer

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:FAP-2286
  • Sponsor:Gemeinnuetzige Salzburger Landeskliniken Betriebsgesellschaft mbH

Prostate cancer metastatic

Not yet recruiting

Study of saruparib plus AR inhibitor drug combination in men with metastatic hormone‑sensitive prostate cancer previously treated with docetaxel or Lu‑PSMA and PSA ≥0.2 ng/mL

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Astrazeneca AB

VEXAS syndrome

Not yet recruiting

A Randomized, Double‑Blind, Placebo‑Controlled Study of Momelotinib Dihydrochloride Monohydrate in Patients with VEXAS Syndrome

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Momelotinib Dihydrochloride Monohydrate
  • Sponsor:Glaxosmithkline Research & Development Limited

Adenocarcinoma pancreas

Not yet recruiting

First‑Line Study of Zoldonrasib (RMC‑9805) Drug Combination vs Gemcitabine/Nab‑Paclitaxel in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Daraxonrasib
  • Sponsor:Revolution Medicines Inc.

Metastatic malignant melanoma+2

Not yet recruiting

Methoxsalen (ECP) versus drug combination for steroid‑refractory immune‑related colitis or hepatitis in metastatic melanoma on checkpoint therapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Therakos Europe Limited

Myasthenia gravis

Not yet recruiting

Efficacy and Safety of DNTH103 in Adults with Generalized Myasthenia Gravis: A Phase 3 Randomized, Double‑Blind, Placebo‑Controlled Study

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:DNTH103
  • Sponsor:Dianthus Therapeutics Inc.

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Bad Dürrnberg

What the registry says about research in the country

01 Women's Health Research

Investigating innovative treatments for menopausal symptoms, specifically focusing on sleep-related challenges that affect women's quality of life.

  • Sleep Disorders
  • Menopausal Health
  • Treatment Evaluation

Current research explores the effectiveness of new therapeutic approaches in managing sleep disturbances associated with menopause, aiming to provide better treatment options for women experiencing these symptoms.

02 Sleep Medicine Studies

Advanced clinical research utilizing polysomnography to evaluate treatment efficacy for sleep-related disorders in menopausal women.

  • Sleep Pattern Analysis
  • Treatment Response
  • Clinical Assessment

Studies employ sophisticated monitoring techniques to understand how novel treatments may improve sleep quality during the menopausal transition.

03 Therapeutic Development

Evaluating the safety and effectiveness of elinzanetant as a potential treatment option for managing menopause-related sleep disruptions.

  • Safety Assessment
  • Efficacy Studies
  • Treatment Innovation

Research focuses on developing targeted therapies to address specific symptoms associated with menopausal transition.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.